RecruitingNot Applicable

Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry

China100 participantsStarted 2026-02-15

Plain-language summary

Research Title：Adult and adolescent hemophilia patients treated with Marstacimab: a patient Experience Registry (AMBER) Protocol Number：94250855 Protocol Version Number：version 0.3 Date：15-November-2024 Leading site：Institution of Hematology \& Blood Diseases Hospital, Chinese Academy of Medical Sciences Active Pharmaceutical Ingredient：a human IgG1 monoclonal antibody that targets the tissue factor pathway inhibitor (TFPI) Drug Name Generic name: marstacimab-hncq Purpose of the Study Primary Objectives:To quantify patient preferences for subcutaneous versus intravenous (IV) injection using the Marstacimab-Patient Preference Questionnaire (M-PPQ) after 1 month of marstacimab for routine prophylaxis treatment. To assess the treatment burden using the Hemophilia Treatment Experience Measure (Hemo-TEM) in hemophilia patients after 6 months of marstacimab for routine prophylaxis treatment. Exploratory Objectives: To evaluate the annualized bleeding rate (ABR) of different types of bleeds after 6 months of subcutaneous marstacimab injections in hemophilia patients. To assess changes in joint status scores between baseline and the final visit after 6 months of subcutaneous marstacimab injections in hemophilia patients, using the Hemophilia Early Arthropathy Detection with Ultrasound in China (HEAD-US-C). To evaluate patient preferences regarding treatment experience via M-PPQ after 6 months

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Participants with a diagnosis of hemophilia A or hemophilia B eligible to receive prophylaxis. Clinical physicians prescribe marstacimab for routine prophylaxis treatment of hemophilia patients based on the actual conditions of the patients and in accordance with the approved indications of marstacimab. Adolescent patients(12 to less than 18 years) and adult (18 years and older) patients. Signed consent obtained before the study, participant or legally authorized representative, or participant's caregiver capable of giving signed informed consent. Exclusion Criteria: \- Those who are unable to complete at least one month follow-up based on the investigator's judgment. Severe impairment of speech, vision, memory or cognition that affects communication and ability to complete questionnaires and follow-up visits. Women of childbearing age who plan to become pregnant within the next 2 months, as well as women who are pregnant or breastfeeding. Patients are participating in other clinical trials. There are other conditions that the investigator deems unsuitable for participation in this study.

What they're measuring

patient preferences for subcutaneous

Timeframe: after 1 month of marstacimab treatment

To assess the treatment burden

Timeframe: after 6 month of marstacimab treatment

Trial details

NCT IDNCT06992076

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-08-31

Contact for this trial

renchi yang, MD

022-23608174 yangrenchi@ihcams.ac.cn